Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 143-149

  Volpe, Donna A ^a   Tomaszewski, Joseph E ^b   Parchment, Ralph E ^a   Garg, Achal ^c   Flora, Karl P ^a   Murphy, Martin J ^c   Grieshaber, Charles K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Cancer Prevention Institute Dayton   (United States)

Author keywords

Bizelesin; CFU gm; Clonal assays; Comparative; In vitro

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BIZELESIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; COLONY FORMATION; CONTROLLED STUDY; DOG; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; DOGS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INDOLES; MALE; MICE; MICE, INBRED BALB C; SPECIES SPECIFICITY; STEM CELLS; UREA;

EID: 0029820713     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050550     Document Type: Article

References (24)

1. Bizelesin Investigator Brochure. August 1993. Division of Cancer Treatment, National Cancer Institute
2. Chidester CG, Krueger WC, Mizsak SA, Duchamp DJ, Martin DG (1981) The structure of CC-1065, a potent antitumor agent, and its binding to DNA. J Am Chem Soc 103:7629
3. DeKoning TF, Postmus RJ, Wallace TL, Kelly RC, Li LH (1990) Therapeutic evaluation of three cyclopropapyrroloindole (CPI) analogs against human tumor xenografts. Proc Amer Assoc Cancer Res 31:348
4. Ding ZM, Hurley LH (1991) DNA interstrand cross-linking, DNA sequence specificity, and induced conformation changes produced by a dimeric analog of (+)-CC-1065. Anticancer Drug Des 6:427
5. Evans E, Kovatch R, Lopez R, Baker J, Mowry B, Smith D, Arneson D, Gatz R, McDermott M, Tomaszewski J (1994) Five daily dose toxicity of bizelesin (NSC-615291) in Fischer 344 rats and beagle dogs. Proc Amer Assoc Cancer Res 35:461
6. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH (1994) Phase-I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst 86:368
7. Gil T, Punt CJ, Kerger J, Kwakkelstein MO, Koier I, Wagener OJ, Piccart MJ (1994) Phase I clinical trial of carzelesin (U80244) administered on a 4-weekly i.v. bolus schedule. Ann Oncol 5[Suppl 5]:137
8. Hanka LJ, Dietz A, Gerphide SA, Kuentzel SL, Martin DG (1978) CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing organism. J Antibiot 31:1211
9. Hightower RD, Sevin BU, Perras J, Nguyen H, Angioli R, Untch M, Averette H (1993) In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecological cancer cell lines. Cancer Invest 11:276
10. Lednicer D, Flora K, Vishnuvajjala R (1994) Ready to use bizelesin. Ann Oncol 5[Suppl 5]:168
11. Lee CS, Gibson NW (1991) DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res 51:6586
12. Lee CS, Gibson NW (1993) Nucleotide preferences for DNA interstrand cross-linking induced by the cyclopropylpyrroloindole analogue U-77,779. Biochemistry 32:2592
13. Li LH, Swenson DH, Schpok SL, Kuentzel SL, Dayton BD, Krueger WC (1982) CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 42:999
14. May RD, Murphy MJ, Erickson-Miller CL, Parchment RE, Tomaszewski JE, Osborn BL, Page JG (1993) Myelotoxicity evaluation of two potential anticancer compounds using murine and human in vitro CFU-GM assays. Proc Am Assoc Cancer Res 34:383
15. McGovren JP, Clarke GL, Pratt EA, DeKoning TF (1984) Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot 37:63
16. Mitchell MA, Kelly RC, Wicnienski NA, Hatzenbuhler NT, Williams MG, Petzold GL, Slightom JL, Siemieniak DR (1991) Synthesis and DNA crosslinking by a rigid CPI dimer. J Am Chem Soc 113:8994
17. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ, Grieshaber CK (1994) An in vivo-in vitro correlation of the myelotoxicity of 9-methoxypyrazoloacridine (PZA, NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine and canine marrow. J Natl Cancer Inst 86:273
18. Rodman LE, Giles HD, Thompson RB, Coffey LB, Tomaszewski JE, Osborn BL, Page JG (1993) Dose range-finding study of bizelesin (NSC-615291) in beagle dogs. Proc Amer Assoc Cancer Res 34:429
19. Sessa C, Pagani O, Zurlo MJ, de Jong J, Hoffman C, Lassus M, Marrari P, Strolin Benedetti M, Cavalli F (1994) Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 5:901
20. Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhart RH (1994) Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drugs 5:10
21. Volpe DA, Du DL, Pohl KP, Campbell JP, Murphy MJ (1991) Utility of human bone marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays. Pathobiology 59:53
22. Volpe DA, Du DL, Zurlo MG, Mongelli N, Murphy MJ (1992) Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human canine and murine hematopoietic progenitor cells. Invest New Drugs 10:255
23. Walker DL, Reid JM, Ames MM (1993) Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol 34:317
24. Warpehoski MA (1991) Dissecting the complex structure of CC-1065. Drugs Future 16:131